Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Free Cash Flow (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Free Cash Flow for 3 consecutive years, with -$12.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow rose 9.04% to -$12.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$77.0 million, a 39.85% decrease, with the full-year FY2025 number at -$77.0 million, down 39.85% from a year prior.
  • Free Cash Flow was -$12.9 million for Q4 2025 at Artiva Biotherapeutics, up from -$19.8 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$10.1 million in Q4 2023 to a low of -$24.1 million in Q2 2025.
  • A 3-year average of -$15.4 million and a median of -$14.1 million in 2024 define the central range for Free Cash Flow.
  • Biggest YoY gain for Free Cash Flow was 9.04% in 2025; the steepest drop was 70.12% in 2025.
  • Artiva Biotherapeutics' Free Cash Flow stood at -$10.1 million in 2023, then tumbled by 40.22% to -$14.1 million in 2024, then grew by 9.04% to -$12.9 million in 2025.
  • Per Business Quant, the three most recent readings for ARTV's Free Cash Flow are -$12.9 million (Q4 2025), -$19.8 million (Q3 2025), and -$24.1 million (Q2 2025).